Image pharmaphorum Editor News US government may cease prescription rebates Pfizer’s CEO believes the US government will eliminate rebates on prescription drugs. News Pioneering Crohn’s antibiotic treatment meets early target A drug targeted at treating Crohn’s disease has shown promise following positive results in a phase 3 trial. Cancer Accord’s biosimilar Pelgraz poised for approval Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP). Cancer FDA approves first drug to treat rare adrenal cancer Azedra has received FDA approval to become the first and only treatment for a type of rare adrenal cancer. Load more results
News US government may cease prescription rebates Pfizer’s CEO believes the US government will eliminate rebates on prescription drugs.
News Pioneering Crohn’s antibiotic treatment meets early target A drug targeted at treating Crohn’s disease has shown promise following positive results in a phase 3 trial.
Cancer Accord’s biosimilar Pelgraz poised for approval Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
Cancer FDA approves first drug to treat rare adrenal cancer Azedra has received FDA approval to become the first and only treatment for a type of rare adrenal cancer.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
